As expected, the number of tumor nodes in mice injected with AAV-ZHX2 were significantly less compared with the control mice, suggesting that ZHX2 suppresses the progression of NAFLD to HCC. The gene discussed is ZHX2; the disease is metabolic dysfunction-associated steatotic liver disease.